Click on a filter below to refine your search. Remove a filter to broaden your search.
Once-weekly efsitora was noninferior to once-daily degludec for a decrease in the mean glycated hemoglobin level.
Black beneficiaries have lower average doses in the first 90 days.
The medication already was approved for advanced disease.
The lifetime use of a standard statin increased quality-adjusted life years by 0.24 to 0.70, with further increase seen for higher-intensity statins.